NCT01130467

Brief Summary

The investigators try to objectively and scientifically explore various brain function impairments in ADHD children by electrophysiologic tests, with and without medication.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

May 24, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 26, 2010

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Last Updated

August 10, 2010

Status Verified

May 1, 2010

Enrollment Period

2.2 years

First QC Date

May 24, 2010

Last Update Submit

August 8, 2010

Conditions

Keywords

Attention Deficit Disorders with HyperactivityAttention Deficit DisorderEvent related potential

Outcome Measures

Primary Outcomes (1)

  • Chinese version of SNAP-IV Rating Scale

    8 weeks

Secondary Outcomes (1)

  • Event-related potential

    8 weeks

Study Arms (3)

Normal control

pure ADHD

Drug: methylphenidateDrug: AtomoxetineBehavioral: behavioral modification

ADHD with comorbidity

Drug: methylphenidateDrug: AtomoxetineBehavioral: behavioral modification

Interventions

IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.

Also known as: Ritalin, Concerta
ADHD with comorbiditypure ADHD

Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).

Also known as: Straterra
ADHD with comorbiditypure ADHD

Parenting and teaching skill education

ADHD with comorbiditypure ADHD

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

One hundred and fifty children, aged 6-18 years old, are enrolled. ADHD children fulfill the DSM-IV-TR criteria for the diagnosis of ADHD. ADHD children are evaluated by Chinese version of SNAP-IV Rating Scale for rating ADHD-related symptoms before and after medication. EEG and audiometric testing are required for every participant to exclude dialeptic seizures and hearing impairment respectively. Urine pregnancy test is performed to exclude pregnant participants. Each participant is evaluated by both pediatric neurologists and child psychiatrists after enrollment to delineate possible underlying comorbidities. Three groups of participants were assigned: normal control group, pure ADHD group and ADHD with comorbidity group.

You may qualify if:

  • health children
  • or clinical diagnosis of attention-deficit hyperactivity disorder

You may not qualify if:

  • hearing impairment
  • uncorrectable visual impairment
  • epilepsy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children Hospital, National Taiwan University Hospital

Taipei, 100, Taiwan

RECRUITING

Related Publications (1)

  • Barry RJ, Johnstone SJ, Clarke AR. A review of electrophysiology in attention-deficit/hyperactivity disorder: II. Event-related potentials. Clin Neurophysiol. 2003 Feb;114(2):184-98. doi: 10.1016/s1388-2457(02)00363-2.

    PMID: 12559225BACKGROUND

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Interventions

MethylphenidateAtomoxetine HydrochlorideBehavior Therapy

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PhenylacetatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPropylaminesAminesPsychotherapyBehavioral Disciplines and Activities

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 24, 2010

First Posted

May 26, 2010

Study Start

September 1, 2009

Primary Completion

December 1, 2011

Last Updated

August 10, 2010

Record last verified: 2010-05

Locations